Fosbretabulin tromethamine


On 21 March 2016, orphan designation (EU/3/16/1633) was granted by the European Commission to Diamond BioPharm Limited, United Kingdom for fosbretabulin tromethamine for the treatment of gastro-entero-pancreatic neuroendocrine tumours.

The sponsorship was transferred to Diamond ROC EOOD, Bulgaria, in March 2019.

The sponsorship was transferred to Diamond Pharma Services Ireland Limited in February 2020.

Key facts

Active substance
Fosbretabulin tromethamine
Intented use
Treatment of gastro-entero-pancreatic neuroendocrine tumours
Date of designation
Orphan designation status
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Diamond Pharma Services Ireland Limited 
Coliemore House
Coliemore Road
Co. Dublin
Tel. 02039119410

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating